<DOC>
	<DOC>NCT02961673</DOC>
	<brief_summary>A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 versus Botox® in Subject with Moderate to Severe Glabellar Lines</brief_summary>
	<brief_title>The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Facial Wrinkle Scale (FWS) score &gt; 2 when Subject knits brow extremely Volunteer who has history of any diseases following. (myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis etc.) From screening, Subject who get a plastic Surgery including fascioplasty, Prosthesis implantation within 6 Weeks Subject who has skin disorder including infection and scar on injection site Subject who takes a medication including skeletal muscle relaxants, Aminoglycoside, lincomycin, anticholinergic drug, benzodiazepine, benzamide etc. Subject who takes a medication including anticoagulant, antithrombotic drug except low dose aspirin (below 325 mg/day) Any condition that, in the view of the investigator, would interfere with study participation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>